Are all prostate cancer patients "fit" for salvage radiotherapy?

Table 3 Exclusion criteria in postoperative radiotherapy phase 3 trials

Postoperative radiotherapy	Trial	Exclusion criteria
Adjuvant RT	EORTC 22911	> 75 yr old
		WHO PS > 1
		PSA > 0.3 ng/mL
	ARO 96-02/AUOAP 09/95	> 75 yr old
		WHO PS > 1
		Detectable PSA
	SWOG 8794	WHO PS > 2
		Total urinary incontinence
		Pelvic infection or urinary extravasation
		Intraoperative rectal injury
Salvage RT ± ADT	RTOG 9601	Life expectancy < 10 yr
		I. Karnofsky < 80%
		Evidence of hepatic disease
		PSA > 4 ng/mL
	GETUG-AFU-16	WHO PS > 1
		Life expectancy < 10 yr
		Inadequate cardiac function
		Another invasive cancer
		PSA > 2 ng/mL
Salvage vs adjuvant RT ± ADT	RAVES 08.03	WHO PS > 1
		Concurrent cytotoxic medication
		Hip prosthesis
		Co-morbidities that would interfere with treatment or 5-yr follow-up
		PSA > 0.10 ng/mL
	RADICALS	Other active malignancy
		PSA > 0.20 ng/mL
	PAC GETUG	WHO PS > 1
		Other active malignancy
		Life expectancy < 10 yr
		PSA > 0.10 ng/mL
		Severe and uncontrolled arterial hypertension

ADT: Androgen-deprivation therapy; PSA: Prostate-specific antigen; PS: Performance status; WHO: World Health Organization; RT: Radiotherapy.